Related Experiment Videos
Effect of diagnosis-related groups on diagnostic methodology in the hospital laboratory
Insights
Physicians must reassess clinical laboratory test utilization under Medicare's diagnosis-related group (DRG) payment system. Evaluating diagnostic value, including sensitivity and specificity, is key for cost-effective laboratory services.
Area of Science:
- Clinical laboratory science
- Health economics
- Hospital administration
Background:
- Physicians traditionally ordered clinical laboratory tests based on various clinical needs.
- Federally mandated prospective payment systems, such as Medicare's diagnosis-related groups (DRGs), have shifted hospital reimbursement models.
- DRG-based payments are fixed per diagnosis, irrespective of the number of laboratory tests performed, necessitating a review of test utilization.
Purpose of the Study:
- To evaluate the appropriateness and level of clinical laboratory services within the context of DRG-based reimbursement.
- To assess the diagnostic value and financial impact of laboratory tests for optimizing resource allocation.
- To analyze microbiology costs associated with high-impact DRG categories in a tertiary care hospital.
Main Methods:
- Review of traditional reasons for ordering clinical laboratory tests.
- Analysis of diagnostic test parameters: sensitivity, specificity, prevalence, speed, and cost of errors (false-negatives/positives).
- Assessment of laboratory test financial impact on both the laboratory and the hospital.
- Identification of high-cost, high-volume DRG categories and their associated microbiology costs.
Main Results:
- DRG payment systems decouple hospital reimbursement from the volume of laboratory tests performed.
- The diagnostic value of laboratory tests must be assessed based on parameters like sensitivity, specificity, and cost-effectiveness.
- Understanding DRG cost, volume, and service utilization is crucial for evaluating laboratory service appropriateness.
- Microbiology costs were analyzed in relation to specific DRG categories within a large, tertiary care hospital.
Conclusions:
- Clinical laboratory test ordering and utilization require strategic review in the era of DRG-based payments.
- Assessing diagnostic value and financial impact is essential for cost-effective laboratory services.
- Targeted analysis of high-impact DRGs can guide the optimization of laboratory resource allocation and service levels.
Abstract:
Traditionally physicians have ordered clinical laboratory tests for a variety of reasons. The establishment of a federally mandated prospective payment system for Medicare patients based on diagnosis-related groups has, among other things, necessitated a review of these reasons as well as the level of use of clinical laboratory services for a given diagnosis. Diagnosis-related group payment to hospitals is independent from the number of laboratory studies performed as long as the diagnosis-related group diagnosis is substantiated at the time the patient is discharged from the hospital. The cost-effective utilization of present tests as well as the adoption of new diagnostic methodologies depends on the assessment of whether a test possesses the appropriate parameters to be of sufficient diagnostic value. These factors include sensitivity, specificity, prevalence, speed, and the costs associated with false-negative or false-positive results. The assessment of the diagnostic value of present or future laboratory methods will require careful analysis relative to their financial impact both within the laboratory and for the hospital as a whole. The laboratory's knowledge of the diagnosis-related group accounting for the highest percentage of their hospital's costs, the highest volume of their cases, and the highest use of their services can aid in assessment of the appropriateness and level of laboratory services. An analysis of the percentage of microbiology costs associated with these diagnosis-related group categories for a large, tertiary care hospital is discussed.